The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma

References

• Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017 Apr 04;14:463 EP.
   Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014 Nov 13;371(20):1867–1876.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 1;372(1):30–39.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA. Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future? J Transl Med. 2017;15(1):173.
   PubMedGoogle Scholar
• Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012 Jul 9;10:85,5876–10–85.
   Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–819.
   PubMed Web of Science ®Google Scholar
• Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan 01;4(1):80.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389–1398.
   PubMed Web of Science ®Google Scholar
• Korn EL, Liu P, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. Jco. 2008 Feb 01; 2018/07;26(4):527–534.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 2018/07;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30; 2018/07;364(26):2517–2526.
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995 Aug 01;182(2):459.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. JCO. 2015 Jun 10; 2018/07;33(17):1889–1894.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. JCO. 2014 Apr 01; 2018/07;32(10):1020–1030.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug 01; 2018/07;16(8):908–918.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016 Mar 02;8(328):328rv4.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 02; 2018/07;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Knowling S, Morris KV. Non-coding RNA and antisense RNA. nature’s trash or treasure? Biochimie. 2011 Nov 01;93(11):1922–1927.
   PubMed Web of Science ®Google Scholar
• The ENCODE PC. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012 Sep 05;489:57.
   PubMed Web of Science ®Google Scholar
• Richtig G, Ehall B, Richtig E, et al. Function and clinical implications of long non-coding RNAs in melanoma. Int J Mol Sci. 2017;18(4).
   PubMed Web of Science ®Google Scholar
• St. Laurent G, Wahlestedt C, Kapranov P. The landscape of long noncoding RNA classification. Trends Genet. 2015 May 01; 2018/07;31(5):239–251.
   PubMed Web of Science ®Google Scholar
• Acunzo M, Romano G, Wernicke D, et al. MicroRNA and cancer–a brief overview. Adv Biol Regul. 2015;57:1–9.
   PubMedGoogle Scholar
• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014 Jul 16;15:509.
   PubMed Web of Science ®Google Scholar
• Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014 Aug 01; 2018/07;20(8):460–469.
   PubMed Web of Science ®Google Scholar
• Fattore L, Costantini S, Malpicci D, et al. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget. 2017;8(13):22262–22278.
   PubMedGoogle Scholar
• Caramuta S, Egyhã¡Zi S, Rodolfo M, et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol. 2010 Aug 01; 2018/07;130(8):2062–2070.
   PubMed Web of Science ®Google Scholar
• Chan E, Patel R, Nallur S, et al. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle. 2011 Apr 06;10(11):1845–1852.
   PubMed Web of Science ®Google Scholar
• Mueller DW, Rehli M, Bosserhoff AK. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatol. 2009 Jul 01; 2018/07;129(7):1740–1751.
   PubMed Web of Science ®Google Scholar
• Fattore L, Sacconi A, Mancini R, et al. MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma. Cytokine Growth Factor Rev. 2017;36:39–48.
   PubMed Web of Science ®Google Scholar
• Li Y, Krahn JM, Flake GP, et al. Towards predicting metastatic progression of melanoma based on gene expression data. Pigment Cell Melanoma Res. 2015 Apr 24;28(4):453–463.
   PubMed Web of Science ®Google Scholar
• Couts KL, Anderson EM, Gross MM, et al. Oncogenic B-raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene. 2012 Jul 02;32:1959.
   PubMed Web of Science ®Google Scholar
• Pinto R, Strippoli S, De Summa S, et al. MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. Expert Opin Ther Targets. 2015 Aug 03;19(8):1027–1035.
   PubMed Web of Science ®Google Scholar
• Lunavat TR, Cheng L, Einarsdottir BO, et al. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. Proc Natl Acad Sci USA. 2017;114(29):E5930–9.
   PubMed Web of Science ®Google Scholar
• Vitiello M, Tuccoli A, D’Aurizio R, et al. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 2017 Feb 06;8(15):25395–25417.
   PubMedGoogle Scholar
• Galasso M, Morrison C, Minotti L, et al. Loss of miR-204 expression is a key event in melanoma. Mol Cancer. 2018;17(1).
   PubMedGoogle Scholar
• Liu S, Lu J, Lee H, et al. miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. Oncotarget. 2014 Jun 20;5(19):9444–9459.
   PubMedGoogle Scholar
• Fattore L, Mancini R, Acunzo M, et al. miR-579-3p controls melanoma progression and resistance to target therapy. Proc Natl Acad Sci USA. 2016;113(34):E5005–13.
   PubMed Web of Science ®Google Scholar
• Poenitzsch AM, Setaluri V, Spiegelman VS. smicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma. Arch Biochem Biophys. 2014 Jul 17;563:118–124.
   PubMed Web of Science ®Google Scholar
• Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009 Feb 01;458(7235):223–227.
   PubMed Web of Science ®Google Scholar
• Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013 Apr 08;10(6):924–933.
   PubMed Web of Science ®Google Scholar
• Huarte M, Guttman M, Feldser D, et al. A large intergenic non-coding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010 Aug 06;142(3):409–419.
   PubMed Web of Science ®Google Scholar
• Martianov I, Ramadass A, Serra Barros A, et al. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. Nature. 2007 Jan 21;445:666.
   PubMed Web of Science ®Google Scholar
• Gutschner T, Hã¤Mmerle M, Eiãÿmann M, et al. The non-coding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2012 Dec 14;73(3):1180–1189.
   PubMed Web of Science ®Google Scholar
• Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 2009 Mar 15;106(28):11667–11672.
   PubMed Web of Science ®Google Scholar
• Hulstaert E, Brochez L, Volders P, et al. Long non-coding RNAs in cutaneous melanoma: clinical perspectives. Oncotarget. 2017 Mar 13;8(26):43470–43480.
   PubMedGoogle Scholar
• Sun C, Li S, Li G, et al. Long intergenic noncoding RNA 00511 acts as an oncogene in non-small-cell lung cancer by binding to EZH2 and suppressing p57. Mol Ther Nucleic Acids. 2016 Sep 09;5(11):e385.
   PubMedGoogle Scholar
• Kotake Y, Nakagawa T, Kitagawa K, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2010 Dec 13;30(16):1956–1962.
   PubMed Web of Science ®Google Scholar
• Xu S, Wang H, Pan H, et al. ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma. Cancer Lett. 2016 Oct 10;381(1):41–48.
   PubMed Web of Science ®Google Scholar
• Lessard L, Liu M, Marzese DM, et al. The CASC15 long intergenic non-coding RNA locus is involved in melanoma progression and phenotype-switching. J Invest Dermatol. 2015 May 27;135(10):2464–2474.
   PubMed Web of Science ®Google Scholar
• Wang J, Pan Y, Wu J, et al. The association between abnormal long noncoding RNA MALAT-1 expression and cancer lymph node metastasis: a meta-analysis. Biomed Res Int. 2015 Jul 14;2016:1823482.
   Google Scholar
• Luan W, Li L, Shi Y, et al. Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22. Oncotarget. 2016 Aug 13;7(39):63901–63912.
   PubMedGoogle Scholar
• Leucci E, Vendramin R, Spinazzi M, et al. Melanoma addiction to the long non-coding RNA SAMMSON. Nature. 2016 Mar 23;531:518.
   PubMed Web of Science ®Google Scholar
• Eleonora L, Coe EA, Marine J-C, et al. The emerging role of long non-coding RNAs in cutaneous melanoma. Pigment Cell Melanoma Res. 2016 Nov 01; 2018/07;29(6):619–626.
   PubMed Web of Science ®Google Scholar
• Tang L, Zhang W, Su B, et al. Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. Biomed Res Int. 2013 May 21;2013:251098.
   PubMed Web of Science ®Google Scholar
• Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by non-coding RNAs. Cell. 2007 Jun 29;129(7):1311–1323.
   PubMed Web of Science ®Google Scholar
• Sousa JF, Torrieri R, Silva RR, et al. Novel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool. PLoS ONE. 2010 Sep 15;5(10):e13510.
   PubMed Web of Science ®Google Scholar
• Goedert L, Pereira CG, Roszik J, et al. RMEL3, a novel BRAF(V600E)-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. Oncotarget. 2016 Apr 16;7(24):36711–36718.
   PubMedGoogle Scholar
• Flockhart RJ, Webster DE, Qu K, et al. BRAF(V600E) remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res. 2012 Apr 11;22(6):1006–1014.
   PubMed Web of Science ®Google Scholar
• Li R, Zhang L, Jia L, et al. Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLOS ONE. 2014 Jun 26;9(6):e100893.
   PubMed Web of Science ®Google Scholar
• Cai B, Zheng Y, Ma S, et al. BANCR contributes to the growth and invasion of melanoma by functioning as a competing endogenous RNA to upregulate Notch2 expression by sponging miR-204. Int J Oncol. 2017;51(6):1941–1951.
   PubMed Web of Science ®Google Scholar
• Keller HR, Zhang X, Li L, et al. Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. Oncotarget. 2017 Jun 05;8(43):75675–75686.
   PubMedGoogle Scholar
• Zhang G, Frederick DT, Wu L, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest. 2016;126(5):1834–1856.
   PubMed Web of Science ®Google Scholar
• Moriceau G, Hugo W, Hong A, et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 9;27(2):240–256.
   PubMed Web of Science ®Google Scholar
• Fattore L, Marra E, Pisanu ME, et al. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med. 2013;11(1):180.
   PubMedGoogle Scholar
• Fattore L, Malpicci D, Marra E, et al. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget. 2015;6(28):24823–24841.
   PubMedGoogle Scholar
• Young HL, Rowling EJ, Bugatti M, et al. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med. 2017;214(6):1691–1710.
   PubMed Web of Science ®Google Scholar
• Hugo W, Shi H, Sun L, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 2015 Sep 10;162(6):1271–1285.
   PubMed Web of Science ®Google Scholar
• Rapino F, Delaunay S, Rambow F, et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature. 2018 Jun 01;558(7711):605–609.
   PubMed Web of Science ®Google Scholar
• Zuo Q, Liu J, Huang L, et al. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. Oncogene. 2018 Jun 01;37(24):3275–3289.
   PubMed Web of Science ®Google Scholar
• Schoumacher M, Burbridge M. Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies. Curr Oncol Rep. 2017;19(3):19.
   PubMed Web of Science ®Google Scholar
• Ahmed F, Haass NK. Microenvironment-driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance. Front Oncol. 2018 May 03;8:173.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2017 Jan 26;168(3):542.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive and acquired resistance to cancer immunotherapy. Cell. 2017 Feb 09;168(4):707–723.
   PubMed Web of Science ®Google Scholar
• Liu S, Tetzlaff MT, Wang T, et al. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell Melanoma Res. 2015 May 16;28(4):431–441.
   PubMed Web of Science ®Google Scholar
• Sun X, Li J, Sun Y, et al. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Oncotarget. 2016 Jun 29;7(33):53558–53570.
   PubMedGoogle Scholar
• Kim J, Ahn J, Lee M. Upregulation of MicroRNA-1246 is associated with BRAF inhibitor resistance in melanoma cells with mutant BRAF. Cancer Res Treat. 2016 Dec 19;49(4):947–959.
   Google Scholar
• DÃaz-MartÃnez M, Benito-JardÃ3n L, Alonso L, et al. miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma. Cancer Res. 2018 Feb 15;78(4):1017.
   PubMed Web of Science ®Google Scholar
• Fattore L, Ruggiero CF, Pisanu ME, et al. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death Differ. 2018 Sep 25.
   PubMed Web of Science ®Google Scholar
• Kozar I, Cesi G, Margue C, et al. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. Biochim Biophys Acta Gen Subj. 2017;1861(11):2980–2992.
   PubMed Web of Science ®Google Scholar
• Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28;5:5241.
   PubMed Web of Science ®Google Scholar
• Li Q, Johnston N, Zheng X, et al. miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget. 2016 Jun 13;7(33):53735–53750.
   PubMedGoogle Scholar
• Audrito V, Serra S, Stingi A, et al. PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. Oncotarget. 2017 Jan 06;8(9):15894–15911.
   PubMedGoogle Scholar
• Wang J, Yu F, Jia X, et al. microRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer. 2014 Aug 30;136(6):E602–13.
   PubMed Web of Science ®Google Scholar
• Heinemann A, Zhao F, Pechlivanis S, et al. Tumor suppressive MicroRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 2012 Jan 15;72(2):460.
   PubMed Web of Science ®Google Scholar
• Joung J, Engreitz JM, Konermann S, et al. Genome-scale activation screen identifies a LncRNA locus that regulates a gene neighborhood. Nature. 2017 Aug 09;548(7667):343–346.
   PubMed Web of Science ®Google Scholar
• Mumford SL, Towler BP, Pashler AL, et al. Circulating MicroRNA biomarkers in melanoma: tools and challenges in personalised medicine. Biomolecules. 2018 Apr 23;8(2):21.
   PubMed Web of Science ®Google Scholar
• Smolle MA, Calin HN, Martin P, et al. Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics. FEBS J. 2017 Jul 01; 2018/07;284(13):1952–1966.
   PubMed Web of Science ®Google Scholar
• Van Laar R, Lincoln M, Van Laar B. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. Br J Cancer. 2018 Jan 23;118:857.
   PubMed Web of Science ®Google Scholar
• Margue C, Reinsbach S, Philippidou D, et al. Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget. 2015 Feb 28;6(14):12110–12127.
   PubMedGoogle Scholar
• Fogli S, Polini B, Carpi S, et al. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol. 2017 May 01; 2018/04;39(5):1010428317701646.
   Google Scholar
• Stark MS, Klein K, Weide B, et al. The prognostic and predictive value of melanoma-related MicroRNAs using tissue and serum: a MicroRNA expression analysis. EBioMedicine. 2015 May 09;2(7):671–680.
   PubMed Web of Science ®Google Scholar
• Alegre E, Sanmamed MF, Rodriguez C, et al. Study of circulating MicroRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med. 2014 Jun 01; 2018/07;138(6):828–832.
   PubMed Web of Science ®Google Scholar
• Vergani E, Di Guardo L, Dugo M, et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget. 2016 Jan 26;7(4):4428–4441.
   PubMedGoogle Scholar
• Hu X, Bao J, Wang Z, et al. The plasma lncRNA acting as fingerprint in non-small-cell lung cancer. Tumor Biol. 2016 Mar 01;37(3):3497–3504.
   PubMedGoogle Scholar
• Ichigozaki Y, Fukushima S, Jinnin M, et al. Serum long non-coding RNA, snoRNA host gene 5 level as a new tumor marker of malignant melanoma. Exp Dermatol. 2016 Jan 01; 2018/10;25(1):67–69.
   PubMed Web of Science ®Google Scholar
• Fleming NH, Zhong J, Da Silva IP, et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer. 2015 Jan 01;121(1):51–59.
   PubMed Web of Science ®Google Scholar
• Friedman EB, Shang S, de Miera EV, et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med. 2012 Aug 02;10:155.
   PubMed Web of Science ®Google Scholar
• Xi J, Huang Q, Wang L, et al. miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. Oncogene. 2018 Jun 01;37(23):3151–3165.
   PubMed Web of Science ®Google Scholar
• Monica C, Scognamiglio G, Laura M, et al. HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease. J Cell Physiol. 2017 Dec 01; 2018/07;232(12):3422–3432.
   PubMed Web of Science ®Google Scholar
• Liu T, Shen S, Xiong J, et al. Clinical significance of long noncoding RNA SPRY4-IT1 in melanoma patients. FEBS Open Bio. 2016 Jan 08;6(2):147–154.
   PubMed Web of Science ®Google Scholar
• Acunzo M, Romano G, Nigita G, et al. Selective targeting of point-mutated KRAS through artificial microRNAs. Proc Natl Acad Sci USA. 2017 May 23;114(21):E4203–12.
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Campani V, Misso G, et al. In vivo activity of MiR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS ONE. 2014 Jan 24;9(2):e90005.
   PubMed Web of Science ®Google Scholar
• Martin Del Campo SE, Latchana N, Levine KM, et al. MiR-21 enhances melanoma invasiveness via inhibition of tissue inhibitor of metalloproteinases 3 expression: in vivo effects of MiR-21 inhibitor. PLoS ONE. 2014 Dec 02;10(1):e0115919.
   Web of Science ®Google Scholar
• Huynh C, Segura MF, Gaziel-Sovran A, et al. Efficient in vivo microRNA targeting of liver metastasis. Oncogene. 2010 Nov 22;30:1481.
   PubMed Web of Science ®Google Scholar
• Wu C, Tan G, Ma C, et al. The non-coding RNA Llme23 drives the malignant property of human melanoma cells. J Genet Genomics. 2013 Apr 20;40(4):179–188.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Menzies AM, Zimmer L, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur j cancer. 2015 Dec;51(18):2792–2799.
   PubMed Web of Science ®Google Scholar
• Parasramka MA, Maji S, Matsuda A, et al. Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol Ther. 2016 May 01;161:67–78.
   PubMed Web of Science ®Google Scholar